Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
المؤلفون المشاركون
Panza, Francesco
Imbimbo, Bruno P.
Santamato, Andrea
Greco, Antonio
Lozupone, Madia
Zecca, Chiara
Barulli, Maria Rosaria
Bellomo, Antonello
Pilotto, Alberto
Daniele, Antonio
Logroscino, Giancarlo
Seripa, Davide
Solfrizzi, Vincenzo
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-15، 15ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-06-26
دولة النشر
مصر
عدد الصفحات
15
التخصصات الرئيسية
الملخص EN
The failure of several Phase II/III clinical trials in Alzheimer’s disease (AD) with drugs targeting β-amyloid accumulation in the brain fuelled an increasing interest in alternative treatments against tau pathology, including approaches targeting tau phosphatases/kinases, active and passive immunization, and anti-tau aggregation.
The most advanced tau aggregation inhibitor (TAI) is methylthioninium (MT), a drug existing in equilibrium between a reduced (leuco-methylthioninium) and oxidized form (MT+).
MT chloride (methylene blue) was investigated in a 24-week Phase II clinical trial in 321 patients with mild to moderate AD that failed to show significant positive effects in mild AD patients, although long-term observations (50 weeks) and biomarker studies suggested possible benefit.
The dose of 138 mg/day showed potential benefits on cognitive performance of moderately affected AD patients and cerebral blood flow in mildly affected patients.
Further clinical evidence will come from the large ongoing Phase III trials for the treatment of AD and the behavioral variant of frontotemporal dementia on a new form of this TAI, more bioavailable and less toxic at higher doses, called TRx0237.
More recently, inhibitors of tau acetylation are being actively pursued based on impressive results in animal studies obtained by salsalate, a clinically used derivative of salicylic acid.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Panza, Francesco& Solfrizzi, Vincenzo& Seripa, Davide& Imbimbo, Bruno P.& Lozupone, Madia& Santamato, Andrea…[et al.]. 2016. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Research International،Vol. 2016, no. 2016, pp.1-15.
https://search.emarefa.net/detail/BIM-1097314
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Panza, Francesco…[et al.]. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Research International No. 2016 (2016), pp.1-15.
https://search.emarefa.net/detail/BIM-1097314
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Panza, Francesco& Solfrizzi, Vincenzo& Seripa, Davide& Imbimbo, Bruno P.& Lozupone, Madia& Santamato, Andrea…[et al.]. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-15.
https://search.emarefa.net/detail/BIM-1097314
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1097314
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر